SIOUX FALLS, S.D.–(BUSINESS WIRE)–January 7, 2020–
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company advancing a new class of immunotherapies, today announced that it has entered into multiple collaboration and option agreements with global biotherapeutics leader CSL Behring. The collaborations will explore the possibility and the potential of new therapies to treat challenging autoimmune, infectious and idiopathic diseases by leveraging SAB’s DiversitAb™ platform.
SAB has developed a unique platform, through advanced genetic engineering, to naturally and rapidly produce large amounts of human antibodies without using human donors.
The agreement includes a research program which will investigate a potential new source for human immunoglobulin G (IgG). Human IgG is currently used for a number of immunological and neurological diseases including Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barre Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), and Multifocal Motor Neuropathy (MMN).
CSL Behring is a leader in the global immunoglobulins market, which has grown substantially over the last five years. Key factors fueling market growth include an aging population, increased emphasis on the diagnosis and treatment of immune diseases, and its increased use in new indications.
“SAB Biotherapeutics has developed a very interesting and novel platform for the production of human immunoglobulins,” said Dr. Andrew Nash, Senior Vice President, Research for CSL Behring. “CSL Behring is committed to the continuous development of innovative therapies that address unmet needs for patients with rare and serious diseases. This collaboration will provide both companies an opportunity to explore the potential of these new approaches to positively impact areas of need.”
CSL Behring’s R&D footprint includes more than 1,700 scientists across the globe with an R&D investment exceeding $800 million in 2018 – 2019.
“We are excited that CSL Behring has chosen to work with SAB Biotherapeutics to explore new immunotherapies leveraging our technology platform,” said Dr. Eddie J. Sullivan, president, CEO and co-founder of SAB Biotherapeutics. “We believe combining our unique human antibody development and production capabilities with CSL Behring’s established immunoglobulin franchise and vast expertise in biopharmaceutical development will broaden therapeutic possibilities.”
CSL Behring and SAB will share research program and related costs and plan to complete the initial phase in 2020. The collaboration may lead to subsequent development and commercialization agreements.
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB), headquartered in Sioux Falls, S.D. is a clinical-stage, biopharmaceutical development company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. Utilizing some of the most complex genetic engineering and antibody science in the world, SAB has developed the only platform that can rapidly produce natural, highly targeted, high-potency, immunotherapies at commercial scale. The company is advancing programs in autoimmunity, infectious diseases, inflammation and exploratory oncology.